CurrentPremera BluecrossPolicy N/A

Neuromuscular Electrical Stimulation (NMES) and Related Electrical Stimulation Devices — Coverage Criteria

This policy governs medical necessity and investigational coverage determinations for neuromuscular electrical stimulation (NMES) devices, conductive garments, and multiple other electrical stimulation modalities for treatment of disuse atrophy, pain, wound healing, tremor, and other indications for Premera Blue Cross members/providers.

Policy Summary

PayerPremera Bluecross

PolicyNeuromuscular Electrical Stimulation (NMES) and Related Electrical Stimulation Devices — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization for NMES billed as E0745 with documentation of disuse atrophy and intact nerve supply; include objective documentation when conductive garments are requested.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

E0745Reimbursable code

several small/industry studiesEvidence base

H-wave, MENS, multimodalInvestigational examples

listedFDA-cleared devices

2025-02-10Last review

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Evidence Summaries

Medical necessity — NMES and conductive garment

Covered when ALL of the following are met

NMES for disuse atrophy

Non-neurological causes: previous casting or splinting of a limb; contractures due to soft tissue scarring from burns; previous major knee surgery (e.g., total knee replacement) with failure to respond to physical therapy; recent hip replacement surgery (up until the time physical therapy begins)
Clinical documentation of disuse atrophy and intact nerve supply required
Conductive garment additional requirements: When a conductive garment is requested, documentation must also show ONE of: treatment site is large making use of many standard electrodes impractical; multiple large treatment sites making standard electrodes impractical; treatment site is hard to reach with standard electrodes and lead wires; OR the individual has skin sensitivity that precludes standard electrodes, adhesive tape, or lead wires.
Documentation of the specific reason for garment necessity must be included in the medical record

Transcutaneous tibial nerve stimulation (Vivally) — evidence summary

Coverage contingent on evidence of clinical benefit demonstrated in trials summarized below; clinical use should align with trial inclusion criteria.

Vivally trial alignment: Patient selection and device use aligned with trial protocols: symptoms of overactive bladder (OAB) for ≥2–3 months; baseline bladder diary showing average daily voids >11 OR ≥1 daily leak on a 3‑day diary; detection of a measurable EMG signal with the device prior to treatment; ability to tolerate 30‑minute sessions; and either drug‑naive status or stable on an OAB medication regimen.as stated

Based on inclusion criteria and procedures reported in Vivally and Zida trials

TENS / supraorbital stimulation for migraine — evidence summary

Device use for acute and preventive migraine has limited and mixed evidence; manufacturer‑sponsored and small trials exist.

Acute migraine TENS: Short‑term trials in emergency department settings showed reductions in pain intensity and medication use within 2 hours after TENS application; generalizability to other settings and long‑term benefit remain unclear.

Evidence downgraded due to inconsistency and heterogeneity

Preventive migraine TENS: One small RCT (N=67) reported a higher proportion of ≥50% responders with TENS versus sham for migraine prevention, but the trial was manufacturer‑sponsored and requires corroboration before definitive conclusions can be drawn.>=50% responder threshold used in trial

May be considered when pharmacologic first‑ or second‑line therapies are inadequate or contraindicated

TEMPR / Scrambler Therapy (Calmare) — evidence summary

Evidence consists of small retrospective and multicenter analyses with heterogeneous populations and variable success rates.

TEMPR outcomes: Uncontrolled and retrospective studies report variable pain reductions (e.g., a small retrospective study reported ~74% pain reduction at 10 days; a multicenter analysis reported a ~38% success rate), but lack of randomized controlled comparative data limits conclusions about net health benefit.

Selection factors (eg, neuropathic vs traumatic etiologies) associated with variable response

Investigational / Not established devices

Devices and modalities with insufficient high‑quality evidence to demonstrate net health benefit are considered investigational or unproven in the literature summarized.

H‑wave: Evidence limited to small controlled trials and insufficient for conclusions; H‑wave electrical stimulation is considered investigational.

See small RCTs and reviews cited

Microcurrent (MENS): Lack of large, well‑controlled trials versus placebo devices; remains investigational.

Historical small trials show no durable or conclusive benefit

Multimodal devices and off‑label uses (eg, NexWave for OAB): No published peer‑reviewed literature to evaluate efficacy of multimodal devices combining IFC/NMES/TENS (eg, NexWave) for many proposed indications; considered unproven/investigational.

PEMF / electromagnetic therapy:

TAPS (Cala Trio) for essential tremor and Parkinson action tremor — evidence summary

Available trials are pragmatic RCT, nonrandomized prospective, and retrospective studies; overall evidence insufficient for conclusive net health benefit.

TAPS evidence: A pragmatic RCT showed reduced tremor power with TAPS (Cala Trio) but had limitations (open‑label elements, short follow‑up, limited analysis of clinically meaningful outcomes). Nonrandomized and retrospective studies suggest safety and potential effectiveness, but comparative data versus pharmacologic therapy are lacking.

Guideline groups (eg, IETF) have suggested TAPS as an add-on option after pharmacologic trials, but evidence remains insufficient for definitive coverage conclusions

Summarized clinical evidence for device groups

Clinical trial evidence summarized (examples):

Transcutaneous tibial nerve stimulation (Vivally, Zida): Randomized and prospective trials reported reductions in OAB endpoints (daily voids, urgency voids/leaks, incontinence) with variable differences versus sham. Primary endpoints used in trials commonly included ≥50% reduction in urgency leaks or ≥30% reduction in 24‑hour voids; some trials demonstrated higher responder rates for active devices versus sham but symptom‑specific differences were sometimes not statistically significant and sample sizes were small.>=50% urgency leak reduction OR >=30% 24-hour void reduction

Examples: Vivally modified ITT response 83.6% vs 57.7% (p=0.032); Zida 80% vs 39% for urgency voids (p=0.02).

External trigeminal nerve stimulation (Monarch eTNS): One RCT in medication‑free children (7–12 yrs) showed improvement on clinician ADHD‑Rating and CGI‑Improvement scales over 4 weeks; trial was small and short‑term and policy assessment deemed evidence insufficient to establish net health outcome improvement for broader populations.clinician ADHD‑Rating scale improvement

Device has FDA de novo clearance for a specific pediatric population but evidence is limited in duration and scope

The policy lists specific devices and modalities that are considered investigational or not eligible for reimbursement. Examples include: galvanic or high‑voltage galvanic stimulation, H‑Wave electrical stimulation, microcurrent electrical nerve stimulation (MENS), and multimodal devices that incorporate interferential current stimulation, NMES, and TENS (e.g., NexWave).

Multimodal devices lacking published peer‑reviewed evidence are described as unproven/investigational. The policy specifically identifies multimodal devices that combine IFC, NMES, and TENS as investigational. H‑wave stimulation and microcurrent (MENS) are also characterized as investigational where controlled, blinded, long‑term comparative data are lacking.

The policy notes common limitations that affect study generalizability and interpretation: many trials have small sample sizes, short follow‑up, industry sponsorship, and participant populations heavily skewed toward females, which limits applicability to males and broader populations.

History entries document that multiple device types and indications have previously been designated investigational. Examples cited in the policy history include pulsed electrical/pulsed electromagnetic therapies, H‑wave stimulation, and other modalities flagged in prior updates.

Across policy history, numerous device types were explicitly labeled investigational in different updates. The history lists items such as pulsed electrical and electromagnetic therapies for osteoarthritis or wound healing, trigeminal nerve stimulation for ADHD, TAPS and wrist stimulation for tremor, multimodal devices (eg, NexWave), and transcutaneous tibial nerve stimulation for overactive bladder as examples of technologies moved into investigational status over time.

The policy states that NMES is considered investigational when used for general muscle strengthening in healthy individuals, cardiac conditioning, treatment of denervated muscles, treatment of idiopathic scoliosis, and other unproven indications.

Evidence summaries for pulsed electromagnetic field therapy (PEMF) indicate mixed study results and methodological limitations. Guideline statements (Academy of Neurology) conclude PEMF is probably not effective for peripheral diabetic neuropathy, and the policy notes a lack of robust evidence supporting other indications.

For external trigeminal nerve stimulation (Monarch eTNS) in ADHD, the policy summarizes a single small randomized trial in children showing short‑term improvements on clinician rating scales but concludes the evidence is insufficient to determine a net health outcome improvement, indicating investigational status for that indication.

Policy history entries include explicit statements that particular devices or therapies were designated investigational in prior versions (for example, pulsed electrical/pulsed electromagnetic therapies and H‑wave stimulation), documenting the evolution of investigational determinations over time.

The policy history records instances where devices or indications were moved between policies or reclassified as investigational, which affected coverage statements. Examples noted include transfers of remote electrical neuromodulation and percutaneous electrical nerve field stimulation to other policy documents and the added investigational designation for transcutaneous tibial nerve stimulation for OAB.

Coding and Supplies

Covered HCPCS CodesHCPCSCovered

E0745

Neuromuscular stimulator; electronic shock unit.

Referenced HCPCS/CPT/Other Codesmixed

E0745	Neuromuscular stimulator; electronic shock unit.
E1399	Durable medical equipment; miscellaneous.
E0761	Nonthermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device.
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve (Monarch eTNS).
E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist (Cala Trio).
E0736	Transcutaneous tibial nerve stimulator (used to report Zida Control Sock).
E0737	Transcutaneous tibial nerve stimulator; controlled by phone application (used to report Vivally System).
A4541	Monthly supplies for use of device coded at E0733.
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist (Cala Trio).
A4545	Supplies and accessories for external tibial nerve stimulator socks, gel pads, electrodes, etc., needed for one month (used to report Vivally System).

1–10 of 13

1/2

Procedure CPT / CategoryCPT

0278T

Transcutaneous electrical modulation pain reprocessing (TEMPR) / Scrambler Therapy

Regulatory identifiers (FDA 510(k) or de novo)mixed

K220454	Vivally System 510(k) clearance identifier
K192731	Zida Control Sock 510(k) clearance identifier
DEN180041	Monarch eTNS de novo identifier
K081255	Calmare Scrambler Therapy 510(k) clearance identifier
DEN170028	Cala ONE de novo pathway identifier
K182706	Cala ONE 510(k) clearance identifier
K203288	Cala Trio 510(k) clearance identifier
K222237	Cala kIQ 510(k) clearance identifier
K111279	NexWave 510(k) clearance identifier

Coding changes and referenced codesmixed

0278T	CPT code added to policy
K1016	HCPCS code added to policy
K1017	HCPCS code added to policy
K1019	HCPCS code description updated
E0762	HCPCS code removed from policy (historical)
E0770	HCPCS code removed from policy (historical)
S8130	HCPCS code removed (historical)
S8131	HCPCS code removed (historical)
L8680	HCPCS/L code removed (historical)
L8679	Code added (historical note)

Coding changes referenced in historymixed

64550	CPT code removed (history entry)
97014	CPT code removed (history entry)
G0283	HCPCS code removed (history entry)
K1023	HCPCS code added then later removed/changed (history entries)
K1016	HCPCS code added then later termed/removed (history entries)
K1017	HCPCS code added then later termed/removed (history entries)
K1018	HCPCS code termed (history entry)
K1019	HCPCS code description updated (history entry)
E0762	HCPCS code removed (history entry)
0720T	CPT code deleted due to criteria change (history entry)

1–10 of 17

1/2

Supply frequency guidance — A4541/A4542/A4545 noted as monthly supplies where applicable

CodesHCPCS supplies A4541, A4542, and A4545 are listed as monthly supplies when applicable (A4541 = monthly supplies for device coded E0733; A4545 = supplies for tibial nerve stim socks, gel pads, electrodes; A4542 = supplies for Cala Trio wrist tremor stimulator).

Reporting periodA4545 noted as needed for one month (new code effective 10/01/24).

Associated device codesThese supply codes correspond to HCPCS device codes E0733, E0734, E0736/E0737 and are used to report monthly consumable supplies.

Vivally inclusion bladder frequency — trial selection criteria

Inclusion bladder frequency

Prior Authorization, Documentation, and Provider Responsibilities

Prior Authorization

Prior Authorization Required (when applicable)

Prior Authorization may be required for some neuromodulation and NMES devices and should be verified prior to ordering. When prior authorization is required, submit complete clinical documentation demonstrating that medical necessity criteria are met.

PA expected for NMES devices billed as HCPCS E0745 when used for disuse atrophy; verify current PA requirements with the payer.
Verify coding and authorization requirements prior to claim submission — CPT/HCPCS codes and PA rules have changed over time (e.g., deletions/edits such as CPT 0720T and historical HCPCS additions/terminations).
Consult member benefit booklets or member services to confirm coverage limits and any plan-specific prior authorization processes.

Documentation Required

Documentation Requirements

Document clinical evidence that the individual meets the medical necessity criteria for the specific device or indication. Provide objective baseline and follow-up measures where applicable.

Conservative Care and Step Therapy Requirements

Treatment Frequency and Session Limits

Supply/frequency guidance — general reference to code‑based frequency limits

General policy guidanceFrequency guidance for supplies and consumables is tied to HCPCS supply codes (e.g., A4541/A4542/A4545) which are described as monthly supplies where applicable.

Coding linkageSupply frequency limits are conveyed via code descriptors in the coding table rather than explicit per‑claim numeric limits in the policy text.

Verify benefitsProviders should verify member benefits and any plan‑specific supply limits at claim submission.

Sympathetic therapy and TEMPR frequency — summary

Treatment frequency characteristicsSympathetic therapy descriptions include daily one‑hour treatments in the physician's office followed by possible home treatments; TEMPR (Scrambler) notes benefit from follow‑up treatments and variable intervals between sessions.

Physiologic Signals and Imaging Requirements

Note

Documentation Required

Transcutaneous tibial nerve stimulation (Vivally)

Vivally and similar TTNS systems required demonstration of a detectable EMG signal with the system as an inclusion requirement in trials.

Detectable EMG signal was required for trial enrollment and is a physiologic confirmation step

Note

Transcutaneous tibial nerve stimulation; Zida sock; Vivally

No imaging studies are required for TTNS devices such as the Zida sock or Vivally per the policy excerpt.

Policy notes 'no' imaging requirement for these wearable devices

Note

Not Covered / Investigational Therapies

The policy’s NOT COVERED / investigational inventory includes numerous examples: galvanic/high‑voltage galvanic stimulation, H‑Wave stimulation, microcurrent/MENS, multimodal devices (eg, NexWave), pulsed electrical and pulsed electromagnetic therapies, and other sympathetic or unproven stimulation devices.

The policy repeatedly lists investigational device examples across sections. Duplicative inventory entries reiterate that galvanic stimulation, H‑Wave, microcurrent, and multimodal devices are considered investigational for all indications where evidence is lacking.

Additional inventory entries duplicate the policy’s investigational list, emphasizing that multimodal devices without peer‑reviewed evidence and specific stimulators such as MENS and H‑Wave remain excluded from established coverage.

The investigational inventory is reiterated elsewhere in the policy, restating that microcurrent (MENS) and similar low‑amplitude therapies lack sufficiently rigorous trials and are therefore considered investigational.

The policy’s not‑covered listings are duplicated in multiple inventory entries to ensure clarity: therapies such as galvanic stimulation, H‑Wave, microcurrent, and multimodal systems are consistently described as investigational.

Several inventory entries repeat that H‑Wave stimulation is investigational given the limited and inconsistent controlled evidence base.

Definitions and Background

Background: Neuromuscular electrical stimulation (NMES) applies surface electrodes to stimulate motor nerves and produce muscle contraction to prevent or retard disuse atrophy, aid muscle re‑education, and increase circulation. The policy addresses open‑loop NMES systems for simple muscle strengthening and related indications; functional (closed‑loop) systems are reviewed under a separate policy.

Conductive garment — definition

DefinitionConductive garment: separated from the individual's skin by a layer of fabric.

Use contextConductive garments are distinguished from direct‑skin electrodes and have additional documentation requirements when requested.

Documentation noteWhen conductive garments are requested, records must show impracticality of standard electrodes or skin sensitivity per policy.

Disuse atrophy — definition

Definition

Policy Summary

PayerPremera Bluecross

PolicyNeuromuscular Electrical Stimulation (NMES) and Related Electrical Stimulation Devices — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization for NMES billed as E0745 with documentation of disuse atrophy and intact nerve supply; include objective documentation when conductive garments are requested.

SourceLink

On This Page

Study results are mixed; systematic reviews and guideline statements (eg, AAN) do not support electromagnetic field therapy for peripheral diabetic neuropathy and Cochrane reviews report no benefit for wound healing; therefore evidence is insufficient.

Sympathetic therapy (Dynatron STS): Limited uncontrolled data with small samples and incomplete reporting; insufficient peer‑reviewed literature to support efficacy — investigational.

Trials required baseline average daily voids > 11 or ≥1 daily leak on a 3‑day bladder diary for Vivally eligibility.

Symptom durationSymptoms of overactive bladder present for 2–3 months at enrollment.

Physiologic confirmationParticipants had to have a detectable EMG signal with the system prior to enrollment.

Primary efficacy endpoint thresholds used in trials

Primary efficacy endpointsCommon primary endpoints in TTNS trials: ≥50% reduction in urgency/urgency‑voids OR ≥30% reduction in 24‑hour voids from baseline.

Example — Zida trialZida primary endpoint defined as 50% reduction in urgency voids or ≥30% reduction in 24‑hour frequency; reported 80% vs 39% success for urgency voids (p=0.02).

Example — Vivally trialVivally randomized trial primary endpoint defined as ≥50% reduction in daily urgency leaks or ≥30% reduction in daily voids; used modified ITT responder analysis (83.6% active vs 57.7% sham).

Literature review period references

Documented literature review periodsPolicy history entries note literature reviews through January 2018, January 2019, January 2020, and January 2022.

Most recent review updateAnnual review updated with literature through October 15, 2024 (history entry 03/01/25).

History timestampsMultiple history entries cite literature review and coding updates across 2018–2024 timepoints (see history entries 05/01/18, 06/01/19, 06/01/20, 06/01/22, 12/01/24, 03/01/25).

For NMES (E0745): clinical documentation must show disuse atrophy with intact nerve supply and a non‑neurological cause (e.g., prior casting/splinting, contracture from burn scarring, failure to respond to physical therapy after major knee surgery, recent hip replacement prior to start of physical therapy).
For conductive garments: include documentation that the treatment site is large or hard to reach, there are multiple large sites, or the member has skin sensitivity precluding standard electrodes.
For TTNS and wearable neuromodulation devices: supply baseline bladder diaries (3‑day/6‑day as used in trials), quality-of-life questionnaires, and evidence of a detectable physiologic signal (e.g., EMG) when required by device trial protocols.
Include trial outcome documentation (e.g., baseline and 12‑week symptom tracking, bladder diaries, QoL scores) and physician assessment of response to therapy.
Lack of documentation showing the above criteria, or reliance on limited/industry‑sponsored evidence, may prompt denial.

Note

Prescription and Clinician Setup

Prescriptions and clinician setup are required for many home-use neuromodulation systems; ensure the prescription and documentation of physician setup or training are included with submissions.

Devices such as the Vivally System and other prescription-only wearables require physician evaluation, initial setup (range of stimulation set by clinician), and oversight of therapy — include documentation that the device was prescribed and the patient instructed on use.
Provide device regulatory and clinical support information (current FDA 510(k)/de novo clearance details and relevant clinical trial citations) when submitting clinical rationale for coverage.

Denial Risk

Denial Risks and Investigational Therapies

Be aware of denial risks and investigational status that may affect coverage decisions.

Therapies or devices designated investigational (for example, pulsed electrical stimulation, PEMF, or multimodal devices that incorporate interferential current stimulation with NMES/TENS) are likely to be denied.
Insufficient or missing objective outcome data, absence of required baseline measures, or lack of evidence of intact nerve supply for NMES indications can trigger denial.
When submitting for devices with limited peer-reviewed evidence or industry‑sponsored studies, include robust supporting documentation and clinician rationale to mitigate denial risk.

Billing Rule

Coding and Billing

Coding and billing must reflect current payer rules and updated code sets; verify codes prior to claim submission to avoid claim denials or miscoding.

Verify current CPT and HCPCS codes — codes have been added, removed, or revised over time (e.g., historical deletions such as CPT 0720T and HCPCS terminations/additions).
When billing NMES, ensure use of the correct HCPCS (e.g., E0745 where applicable) and include required supporting documentation to justify medical necessity.
Coordinate with payer prior authorization teams if there is uncertainty about code applicability or coverage status.

No explicit payer limits

Policy excerpts do not specify numerical per‑period frequency limits for sympathetic therapy or TEMPR; scheduling varies by manufacturer protocols and clinical response.

Clinical settingSome TEMPR treatments are to be administered under direct physician supervision by certified clinicians per device guidance.

Trial schedules referenced — example session regimens

Common trial schedulesClinical trials referenced schedules such as 30‑minute sessions once weekly for 12 weeks (Zida) or 30‑minute sessions three times weekly for 12 weeks (Vivally randomized trial).

Session durationTreatment session length reported as 30 minutes in multiple TTNS trials and device instructions.

No explicit policy limitsThe policy does not impose explicit coverage frequency limits based on these trial schedules; they are presented as examples from the literature.

Placeholder

Placeholder 2

Placeholder 3

Placeholder

Placeholder 2

Placeholder 3

Inventory entries reiterate that multimodal devices that combine IFC, NMES, and TENS have no published peer‑reviewed literature to support efficacy and are therefore investigational.

Duplicate not‑covered inventory statements further emphasize that microcurrent electrical nerve stimulation (MENS) lacks large controlled trial evidence and remains investigational.

Multiple inventory entries restate that galvanic/high‑voltage galvanic stimulation is considered investigational for chronic pain and other indications.

The policy inventory repeats that investigational items include multimodal devices and specific named examples (eg, NexWave) when used off‑label for conditions such as OAB.

Several duplicated inventory entries emphasize the investigational status of therapies without adequate evidence, including H‑Wave and similar devices.

Inventory duplicates reiterate that listed modalities are not eligible for reimbursement when designated investigational in the policy (eg, microcurrent, H‑Wave, galvanic).

The policy contains multiple identical not‑covered entries underscoring investigational designations for modalities such as multimodal devices and MENS.

Repeated inventory items in the policy reinforce that therapies like galvanic stimulation, H‑Wave, and microcurrent are investigational and not covered.

The policy concludes that evidence is insufficient to determine that external trigeminal nerve stimulation (eTNS) improves net health outcomes for ADHD based on the single small pediatric RCT, implying noncoverage or investigational status for that indication.

Additional duplicated not‑covered inventory entries restate the investigational status of listed electrical stimulation modalities (eg, MENS, H‑Wave, multimodal devices) across the policy.

The inventory includes multiple repeated entries noting investigational modalities; these duplicates highlight the consistent policy stance that devices without sufficient peer‑reviewed evidence are not covered.

The policy’s repeated not‑covered listings underscore that technologies such as galvanic stimulation, H‑Wave, microcurrent, and multimodal systems remain investigational in the absence of robust evidence.

Duplicate inventory statements reiterate investigational determinations for the same set of devices and modalities across policy sections.

The policy contains numerous repeated not‑covered listings for modalities lacking sufficient evidence (eg, H‑Wave, microcurrent, multimodal devices), which are presented across inventory entries.

Inventory duplicates reaffirm that the listed investigational therapies are not eligible for reimbursement under the policy statements.

The policy’s multiple inventory entries repeat the same investigational device examples to ensure clarity for providers and reviewers.

Additional duplicate not‑covered entries emphasize that devices without sufficient peer‑reviewed evidence (eg, NexWave multimodal device) are considered investigational.

Repeated inventory lines in the policy stress that therapies like microcurrent and galvanic stimulation are investigational across multiple not‑covered lists.

Several identical inventory entries restate the investigational status of the same device groups to avoid ambiguity in coverage decisions.

The policy’s repeated not‑covered inventory entries make explicit that modalities without adequate evidence are excluded from established coverage.

Duplicate inventory notes continue to list investigational examples (eg, H‑Wave, galvanic, MENS, multimodal devices) that are not supported for reimbursement.

Disuse atrophy: Gradual wasting or deterioration of a muscle when not used or subjected to prolonged inactivity.

Typical scenarioExample: muscle wasting when an arm is immobilized in a cast for an extended period.

Policy relevanceDisuse atrophy (with intact nerve supply) is a required criterion for NMES (E0745) medical necessity.

Neurogenic atrophy — definition

DefinitionNeurogenic atrophy: Muscle atrophy due to nerve injury or disease; tends to occur suddenly.

ContrastDistinguished from disuse atrophy which is gradual; neurogenic atrophy implies nerve compromise and is treated differently in policy.

Coverage implicationNMES coverage requires intact nerve supply, so neurogenic atrophy is generally not the target indication for NMES under E0745.

Muscle atrophy — definition

DefinitionMuscle atrophy: Muscle wasting or tissue loss that occurs when a muscle is no longer as active as usual, leading to weakness.

ScopeEncompasses both disuse and neurogenic causes; policy differentiates indications for coverage accordingly.

Clinical noteIdentification of the underlying cause (disuse versus neurogenic) is required in medical records for coverage decisions.

Sympathetic therapy — definition

DefinitionSympathetic therapy: electrical stimulation of peripheral nerves intended to stimulate the sympathetic nervous system to normalize autonomic function and reduce sympathetically mediated pain.

DeliveryUses multichannel intersecting frequencies and bilateral electrode placement; may include daily one‑hour office treatments followed by home treatments.

Evidence noteEvidence for effectiveness is limited and small studies exist; policy lists sympathetic stimulation among investigational modalities.

TEMPR / Scrambler Therapy (CPT 0278T) — definition

DefinitionTEMPR / Scrambler Therapy (CPT 0278T): transcutaneous electrical modulation reprocessing using devices (eg, Calmare) that aim to transmit a 'no‑pain' signal via surface electrodes to disrupt pain perception pathways.

AdministrationMaximal benefit often requires a course of follow‑up treatments; treatment is performed under physician supervision by trained clinicians.

CodingCPT 0278T describes TEMPR / Scrambler therapy per policy coding table.

Cala Trio / TAPS — definition

DefinitionCala Trio / TAPS: transcutaneous afferent patterned stimulation delivered via a wrist‑worn device to median and radial nerves to reduce upper‑limb tremor.

Device statusCala devices have de novo/510(k) regulatory summaries (Cala ONE de novo DEN170028; Cala Trio K203288; Cala kIQ K222237).

Indication nuancePolicy designates TAPS investigational for essential tremor and action tremor associated with Parkinson disease for coverage purposes.

Transcutaneous tibial nerve stimulation (TTNS) — definition

DefinitionTranscutaneous tibial nerve stimulation (TTNS): non‑invasive surface electrode stimulation of the tibial nerve to modulate sacral nerve pathways and reduce overactive bladder symptoms.

ExamplesDevices include Vivally (phone‑app controlled wearable) and Zida Control Sock; typical sessions are 30 minutes once weekly or 30 minutes 1–3 times weekly per trial designs.

Prescription statusThese systems are prescription‑only and used at home after physician setup of stimulation parameters.

Vivally System — definition

DefinitionVivally System: a noninvasive wearable bladder control therapy system utilizing neuromodulation to treat urge urinary incontinence and urinary urgency by stimulating the tibial nerve (FDA 510(k) K220454).

Device featuresVivally is controlled by a phone app, includes EMG sensors, and records bladder diaries and adherence data in a cloud database for physician monitoring.

Trial requirementsVivally trial participants required detectable EMG signal, tolerance of 30‑minute sessions, and symptom duration/prior medication stability per study protocols.

Zida Control Sock — definition

DefinitionZida Control Sock: a wearable neuromodulation system intended to treat overactive bladder symptoms via transcutaneous stimulation of the posterior tibial nerve near the ankle (FDA 510(k) K192731).

Usage regimenZida trial protocol used once‑weekly 30‑minute sessions for 12 weeks in randomized studies.

Trial outcomesIn the referenced trial the Zida group achieved higher responder rates for urgency voids versus sham (80% vs 39%).

Cala devices (TAPS) — definition

DefinitionCala devices (TAPS): Cala Trio / Cala kIQ deliver transcutaneous afferent patterned stimulation to median and radial nerves to provide temporary relief of hand tremors.

Regulatory notesCala ONE received de novo (DEN170028) and subsequent 510(k) clearances (K182706, K203288, K222237) as noted in regulatory summaries.

ContraindicationsDevice labeling includes contraindications (eg, implanted electrical devices, epilepsy, pregnancy).

Monarch eTNS System — definition

DefinitionMonarch eTNS System: external trigeminal nerve stimulation (eTNS) system cleared by FDA via de novo (DEN180041) for treatment of ADHD in children 7–12 years not taking prescription ADHD medication.

Use settingPrescription device intended for home use under caregiver supervision; generates low‑level electrical pulses applied to forehead patch.

Evidence notePolicy notes limited trial duration and sample size; evidence excerpt judged insufficient for net health outcome improvement for eTNS in ADHD in adult policies.

Regulatory device summaries — de novo/510(k) decisions referenced

Regulatory summariesPolicy references multiple FDA 510(k) and de novo decisions (examples: Cala ONE DEN170028; Cala Trio K203288; Zida K192731; Vivally K220454; NexWave K111279).

Access to summariesReferences list FDA 510(k) summaries and de novo decision documents with accession dates provided in the references.

ImplicationDevice regulatory clearance is documented but does not by itself determine coverage; policy applies evidence‑based review for coverage decisions.

Investigational — policy history meaning

Definition in policy history'Investigational' in policy history denotes devices or therapies judged to lack sufficient evidence for coverage for specified indications.

ExamplesHistory entries list multiple therapies labeled investigational over time (eg, pulsed electrical/electromagnetic therapy, H‑wave, REN, PENFS, TAPS for certain indications).

Coverage effectDesignation as investigational across history entries signals potential for claim denial absent new evidence or guideline changes.